Business Wire

ORAL-NICOTINE-COMMISSION

6.12.2022 08:03:40 CET | Business Wire | Press release

Share
Sweden Achieves the Lowest Smoking Rate in Europe and is on Track to Become Officially Smoke-Free - The EU Must Take Note

Swedish authorities officially confirmed that the current level of smoking in Sweden has fallen to 5,6%. This makes Swedes the only European nation close to reaching the smoke-free goal set by the EU 18 years ahead of the 2040 target.

In an event organised by the Oral Nicotine Commission in Stockholm, participants took stock of Sweden’s incredible achievements and leadership in the race to end smoking. It is about to become the first country in the world to be defined as “smoke free”, representing a share of less than 5% of the population smoking.

Sweden’s smoking rates have shot down since the 1980s from 35% down to below 6% - a feat that is yet to be replicated by any other nation in the world. The next lowest smoking rate in Europe is double that of Sweden’s, with the EU average sitting somewhere around 23%, four times higher than in Sweden. The result is the lowest tobacco mortality rate in Europe.

A group of leading public health professionals, consumer advocates and harm reduction experts that met to celebrate the achievement on 30 November 2022 in Stockholm have reaffirmed their call to policymakers around the world to ensure that less harmful alternatives to smoking are available to support smokers to quit.

Commenting at the event, Dr. Delon Human, President of Health Diplomats and organiser of the event in Stockholm said: “If all smokers in the world, some 1.1 billion people, would switch to one of less harmful alternative smoke-free, nicotine-based products, it could prevent disease and save millions of lives worldwide. Sweden has found the fire-escape for smokers. We need to work together to repeat the Swedish experience globally to save lives.”

This incredible success story gave attendees the chance to better understand Sweden’s recipe to success, key to which is its openness to less harmful alternatives to smoking. Snus has been at the forefront of the reduction measures, but in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers aiming to quit.

The progressive, pro harm-reduction Swedish model is clearly distinct from the policies proposed by international organisations in favour of tobacco control. At an EU level, harm reduction advocates have fought hard to have harm reduction recognised in the European Beating Cancer Plan. The WHO still refuses to acknowledge its value, despite the fact that harm reduction is explicitly recognised in the Framework Convention for Tobacco Control.

Commenting at the event, Professor Karl Fagerström said: “The upcoming Swedish EU presidency is a great opportunity to share their 5% success story to other EU countries. We hope that Sweden will be generous with sharing this know-how internationally.”

Speakers at the conference emphasised the need for sound evidence-based policy interventions in tobacco control. This translates to the broad adoption of tobacco harm reduction policies that support a journey to quitting smoking.

Ensuring that less harmful alternatives to smoking are affordable, accessible and affordable will be paramount to ensure that other countries can replicate Sweden’s success. This event is the start of much needed discussion of this topic.

The Oral Nicotine Commission is a global not-for-profit association that helps build the evidence base and raise awareness of Oral Nicotine among both governments, public health leaders and the public, thus countering negative, unfounded preconceptions and stereotypes. It addresses policy, science, consumer issues and relevant product innovations. Its views are independent of any brand or manufacturer and focuses on the individual and population health needs of adult smokers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005671/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye